Products
Products

TruSight Oncology 500 clinical research solutions

Take cancer from uncertainty to insight

Enable comprehensive genomic profiling from tissue or liquid biopsies for clinical research

Profile image of a female scientist using a single pipette into a tube, two boxes of TruSight Oncology ctDNA v2 Enrichment library prep boxes on the lab bench with other NovaSeq X consumables; two scientists and a NovaSeq X instrument are blurry in the background.

Streamlined assays to fuel precision oncology research

The TruSight Oncology 500 product line offers pan-cancer next-generation sequencing assays to enable in-house comprehensive genomic profiling (CGP). Identify relevant biomarkers from key guidelines and clinical trials with one consolidated assay to get more results with less sample than iterative testing. 

TruSight Oncology 500 products

TruSight Oncology 500 v2*

Enable CGP findings faster from FFPE tissue with a more efficient workflow, using a comprehensive pan-cancer panel that covers all major variant classes and gene signatures (TMB, MSI, and HRD).

TruSight Oncology 500 ctDNA v2

Enable CGP with a pan-cancer panel capable of detecting key IO gene signatures (TMB, MSI) plus all main variant classes from ctDNA in blood plasma.

Key features and benefits

Comprehensive

Assess >500 pan-cancer biomarkers in a single multiplex assay, including broad genomic signatures like TMB, MSI and HRD* to increase the likelihood of identifying a relevant mutation without sequential testing.

Flexibility

Use FFPE samples or minimally invasive circulating tumor DNA (ctDNA) from liquid biopsy to complement tissue studies or if sufficient tissue is not readily available.

Reliability

Achieve consistent quality across the portfolio with robust hybrid capture chemistry, proven SBS sequencing and sophisticated bioinformatics.

In-house

Offer precision oncology in your lab to minimize sample loss, control turnaround times, monitor quality, and retain data for reanalysis as discoveries are made.

Timely

Obtain results in 3-4 days with integrated library prep, sequencing, and bioinformatics options available locally or in the cloud.

Scalable

Reduce hands-on time and minimize errors with automation options. Sequence 8–960 samples per run for TruSight Oncology v2 and 8–48 samples per run for TruSight Oncology 500 ctDNA.

Key biomarkers

Subset of genomic tumor profiling biomarkers for multiple cancer types

Pan-cancer: BRAF, NTRK1, NTRK2, NTRK3, RET, TMB, MSI

Genes with biomarkers of significancea
  Breast AKT1 BRCA1 BRCA2 ESR1 PIK3CA PTEN
  Colorectal KRAS NRAS POLD1 POLE    
  Lung ALK BRAF EGFR ERBB2 KRAS MET
RET ROS1        
  Melanoma KIT NRAS        
  Ovarian BRCA1 BRCA2 HRD      
  Prostate ATM ATR BARD1 BRCA1 BRCA2 BRIP1
CDK12 CHEK1 CHEK2 FANCL MRE11A NBN
PALB2 RAD51B RAD51C RAD51D RAD54L  
  Uterine POLE          

The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on the respective product pages.

  1. Genes with biomarkers of significance linked to major guidelines.

Product comparison

  TruSight Oncology 500 v2* TruSight Oncology 500 ctDNA v2
Assay time 3–4 days from sample input to final results 3–4 days from purified nucleic acid to variant report
Automation capability Liquid handling robot(s) Liquid handling robot(s)
Automation details Explore available automation methods Explore available automation methods
Cancer type Pan-cancer, Solid tumor Pan-cancer, Solid tumor
Content specifications
  • Targeted sequencing of DNA from 523 genes and RNA from 55 genes for a total of 1.94 Mb panel size. MSI and TMB measurement included. 
  • The included HRD (homologous recombination deficiency) panel includes coverage of ~25K SNPs to assess HRD through a comprehensive genomic instability score (LOH+TAI+LST) powered by Myriad Genetics.
  • Immuno-oncology biomarker coverage: TMB and MSI
  • Guideline coverage: Broad coverage of key guidelines for multiple solid tumor types
  • Clinical trial coverage: Over 600 clinical trials (based on Velsera Knowledgebase, as of February 2023).
Description Enables comprehensive genomic profiling of solid tumors using DNA and RNA from FFPE tissue. Provides variant detection and biomarker assessment from a single sample for broad tumor characterization. Provides a noninvasive research method for comprehensive genomic profiling of liquid biopsy samples (ctDNA from blood plasma). This liquid biopsy approach provides insights about intra- and inter-tumor heterogeneity using a minimally invasive sample collection approach to complement tissue-based CGP.
Hands-on time ~7 hrs for manual workflow ~1.5 hr for automated workflow
~2.5 hr for manual workflow
Input quantity 30 ng DNA (as low as 10 ng), 40 ng RNA (as low as 20 ng) 20 ng cfDNA (4 ml of plasma)
Instruments NextSeq 550 System, NextSeq 2000 System, NextSeq 1000 System, NextSeq 550Dx in Research Mode, NovaSeq X System, NovaSeq 6000Dx in Research Mode, NovaSeq 6000 System, NovaSeq X Plus System NovaSeq X System, NovaSeq X Plus System, NovaSeq 6000 System, NovaSeq 6000Dx in research mode
Method Targeted DNA sequencing, Targeted RNA sequencing, Target enrichment Target enrichment, Targeted DNA sequencing
Multiplexing NextSeq 550/Dx: 8 samples/run.
NexSeq 1000 and 2000: P2 flow cell 8 samples, P3 flow cell 24 samples, P4 flow cell 36 samples.
NovaSeq 6000/Dx: SP flow cell 16 samples, S1 flow cell 32 samples, S2 flow cell 72 samples, S4 flow cell 192 samples.
NovaSeq X/X+: 1.5 B 32 samples, 10B 192 samples, 25B 480 samples.		 NovaSeq X Series: 4 samples on 1.5B flow cell, 24 samples on 10B flow cell
NovaSeq 6000 System: 8 samples on S2 flow cell, 24 samples on S4 flow cell, 192 indexes maximum
Nucleic acid type RNA, DNA DNA
Sample throughput 8–960 samples/run 4-48 samples/run
Specialized sample types FFPE Tissue Circulating tumor DNA, Blood
Species category Human Human
Technology Sequencing Sequencing
Variant class Gene fusions, Loss of heterozygosity (LOH), Somatic variants, Transcript variants, Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs), Genomic instability score (GIS), Microsatellite instability (MSI), Tumor mutational burden (TMB), Novel transcripts, Single nucleotide polymorphisms (SNPs), Structural variants Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs)

FAQ

TruSight Oncology 500 v2 and TruSight Oncology 500 ctDNA v2 cover 523 cancer-related genes across DNA and RNA variants. (RNA variants are included with the TruSight Oncology 500 v2 tissue-based assays only.) Genes were chosen based on alignment to guidelines, drug labels and clinical trials across multiple solid tumor types. For more details and the full gene list, see the TruSight Oncology 500 v2 and TruSight Oncology 500 ctDNA v2 data sheet.

The TruSight Oncology 500 v2 assay includes the probes necessary to help labs enable the assessment of genomic instability (GIS) and unlock tumor insights relevant for ovarian, breast, pancreatic, and prostate cancers.3

TruSight Oncology 500 ctDNA v2 includes similar content to TruSight Oncology 500 v2, but gene fusions are called from DNA only across 23 genes (compared to 55 for tissue). Additionally, HRD assessment is not included for TruSight Oncology 500 ctDNA v2.

/ Results

Resources

Thumbnail

Advancing Cancer Research with TSO 500 v2 at the Catalan Institute of Oncology

Learn how researchers at the Catalan Institute of Oncology are using TruSight Oncology 500 v2 to streamline their workflow and accelerate their research. In this video, scientists from the institute talk about the improved assay and share how faster results help to drive discovery

Speak to a specialist

Contact an Illumina representative to learn more about TruSight Oncology 500 products and find the right assay for your needs.

*TruSight Oncology v2 is not available for sale in Japan.

 

References

  1. Content analysis provided by Pierian Knowledgebase v8.5, February 2023.
  2. O'Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547-560. doi:10.1016/j.molcel.2015.10.040 
  3. Yamamoto H, Hirasawa A. Homologous recombination deficiencies and hereditary tumors. Int J Mol Sci. 2021;23(1):348. doi:10.3390/ijms23010348